ALLERFLORA
Allergy & Immunology
- Promotes a balanced Th1/Th2 immune response
- Promotes production of anti-inflammatory IL-10 cytokine
- Reduces the severity of allergic rhinitis-related symptoms, and the need for antihistamines
Lactiplantibacillus plantarum LP01 (LMG P-21021)
Lacticaseibacillus paracasei LPC00 (LMG P-21380)
Fructooligosaccharides (FOS)
This combination of Lactiplantibacillus plantarum LP01 and Lacticaseibacillus paracasei LPC00 is specifically designed to target the strong Th2-driven inflammation commonly observed in allergic patients. Both LP01 and LPC00 strains exhibit anti-Th2 driven activity, playing a crucial role in rebalancing the upregulated expression of Th2 cytokines associated with allergic diseases and increasing the production of IL-10 [1,2].
ALLERFLORA® underwent clinical evaluation in a multicenter randomized controlled trial (RCT) against a placebo, focusing on adults with perennial allergic rhinitis [3]. During the study, a 4-month supplementation with ALLERFLORA® once daily led to:
- A significant reduction in total nasal symptoms after 2 and 4 months.
- A substantial decrease in the ARIA classification compared to the baseline (p<0.005 and p=0.02, respectively).
- Additionally, the use of antihistamine drugs and intranasal corticosteroids notably decreased after 2 and 4 months (p<0.0001).
1. Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214.
2. Internal Probiotical data
3. Manzotti G. et al., Multi-strain Symbiotic Preparations as a Novel Adjuvant Approach to Allergic Rhinitis. J Contemp Immunol. 2014 Oct 11;1(2):67-80. Doi: 10.7726/JCI.2014.1008
